Please login to the form below

Not currently logged in
Email:
Password:

Colobreathe

This page shows the latest Colobreathe news and features for those working in and with pharma, biotech and healthcare.

NICE gives final ‘yes’ to cystic fibrosis drugs from Novartis and Forest

NICE gives final ‘yes’ to cystic fibrosis drugs from Novartis and Forest

NICE backs Tobi Podhaler and Colobreathe for NHS use. Cystic fibrosis patients in England and Wales will now have access to two new drugs from Novartis and Forest Laboratories to treat ... The limited recommendation takes into account that the Tobi

Latest news

  • NICE backs two cystic fibrosis treatments for NHS use NICE backs two cystic fibrosis treatments for NHS use

    Novartis’ Tobi Podhaler and Forest’s Colobreathe recommended at discounted price. Novartis' Tobi Podhaler and Forest Laboratories' Colobreathe have both received backing for use in the NHS in England and Wales ... NICE had previously ruled that there

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics